Osteoarthritis is a chronic degenerative disease with progressive slow development, and is the most common form of arthritis, characterized by wear and tear and destruction of articular cartilage, with clinical manifestations of joint pain, swelling, joint deformity, and limited mobility.The incidence of osteoarthritis in people over 75 years of age ranges from 70 to 90%, with an earlier onset in females than in males, and ultimately a similar incidence in both males and females. Clinical treatment includes non-surgical and surgical treatment. The former is the mainstay. Pharmacological treatment constitutes the main component of non-surgical treatment, including acetaminophen, non-steroidal anti-inflammatory analgesics, weak central analgesics, glucosamine, hyaluronic acid, hormones, etc. Among them, acetaminophen and non-steroidal anti-inflammatory analgesics have become the most commonly used first-line medications in the treatment of osteoarthritis because of their ability to relieve pain and control symptoms. Glucosamine, a naturally occurring amino monosaccharide derived from crabs and other shelled marine organisms, is an important structural component of glycosaminoglycans and hyaluronic acid, and thus serves as a substitute for endogenous articular cartilage nutrients. It can stimulate chondrocytes to produce proteoglycans with normal multimeric structure, improve the repair ability of chondrocytes, inhibit the release of hydrolytic enzymes such as lysosomal enzymes, collagenase and phospholipase A2, reduce the hydrolytic destruction of articular cartilage matrix, and prevent the generation of superoxide radicals that damage the cells and promote the repair and reconstruction of the cartilage matrix, thus slowing down the pathological process of osteoarthritis and the course of the disease. As a nutritional supplement for articular cartilage, glucosamine has been used in the prevention and treatment of osteoarthritis for a long time, as early as the 1960s glucosamine began to be used in Europe for the treatment of arthritis, and it became popular in the United States in the mid-1990s, and it is still the most popular nutritional drug for articular cartilage in the U.S., supplying to the market in the form of food and health care, and it has been recognized in Europe as the most effective product for the clinical treatment of osteoarthritis because of its demonstrated clinical efficacy. In Europe, the product is regulated and available to patients as a prescription drug due to its demonstrated clinical efficacy. It is precisely because glucosamine has the potential to modify the structure of articular cartilage. It is because of its potential to modify the structure of articular cartilage, regulate the metabolism of articular cartilage, and even have the potential to slow the progression of arthritis by repairing damaged articular cartilage, that these products have the potential to improve the condition of osteoarthritis.